Literature DB >> 15246368

Experiment assessment of mass effects in the rat: implications for small animal PET imaging.

E M Jagoda1, J J Vaquero, J Seidel, M V Green, W C Eckelman.   

Abstract

In vivo imaging using positron emission tomography (PET) is important in the development of new radiopharmaceuticals in rodent animal models for use as biochemical probes, diagnostic agents, or in drug development. We have shown mathematically that, if small animal imaging studies in rodents are to have the same "quality" as human PET studies, the same number of coincidence events must be detected from a typical rodent imaging "voxel" as from the human imaging voxel. To achieve this using the same specific activity preparation, we show that roughly the same total amount of radiopharmaceutical must be given to a rodent as to a human subject. At high specific activities, the mass associated with human doses, when administered to a rodent, may not decrease the uptake of radioactivity at non saturable sites or sites where an enzyme has a high capacity for a substrate. However, in the case of binding sites of low density such as receptors, the increased mass injected could saturate the receptor and lead to physiologic effects and non-linear kinetics. Because of the importance of the mass injected for small animal PET imaging, we experimentally compared high and low mass preparations using ex vivo biodistribution and phosphorimaging of three compounds: 2-fluoro-2-deoxyglucose (FDG), 6-fluoro-L-metatyrosine (FMT) and one receptor-directed compound, the serotonin 5HT1A receptor ligand, trans-4-fluoro-N-[2-[4-(2-methoxylphenyl) piperazino]ethyl]-N-(2-pyridyl) cyclohexane- carboxamide (FCWAY). Changes in the mass injected per rat did not affect the distribution of FDG, FMT, and FCWAY in the range of 0.6-1.9 nmol per rat. Changes in the target to nontarget ratio were observed for injected masses of FCWAY in the range of approximately 5-50 nmol per rat. If the specific activity of such compounds and/or the sensitivity of small animal scanners are not increased relative to human studies, small animal PET imaging will not correctly portray the "true" tracer distribution. These difficulties will only be exacerbated in animals smaller than the rat, e.g., mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246368     DOI: 10.1016/j.nucmedbio.2004.04.003

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  25 in total

1.  Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies.

Authors:  Goran Laćan; Alain Plenevaux; Daniel J Rubins; Baldwin M Way; Caroline Defraiteur; Christian Lemaire; Joel Aerts; André Luxen; Simon R Cherry; William P Melega
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-05       Impact factor: 9.236

Review 2.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

3.  Performing radiosynthesis in microvolumes to maximize molar activity of tracers for positron emission tomography.

Authors:  Maxim E Sergeev; Mark Lazari; Federica Morgia; Jeffrey Collins; Muhammad Rashed Javed; Olga Sergeeva; Jason Jones; Michael E Phelps; Jason T Lee; Pei Yuin Keng; R Michael van Dam
Journal:  Commun Chem       Date:  2018-03-22

4.  Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide.

Authors:  Elaine M Jagoda; Sibaprasad Bhattacharyya; Joseph Kalen; Lisa Riffle; Avrum Leeder; Stephanie Histed; Mark Williams; Karen J Wong; Biying Xu; Lawrence P Szajek; Osama Elbuluk; Fabiola Cecchi; Kristen Raffensperger; Meghana Golla; Donald P Bottaro; Peter Choyke
Journal:  Mol Imaging       Date:  2015       Impact factor: 4.488

5.  Simultaneous dual-tracer PET imaging of the rat brain and its application in the study of cerebral ischemia.

Authors:  Francisca P Figueiras; Xavier Jiménez; Deborah Pareto; Vanessa Gómez; Jordi Llop; Raul Herance; Santiago Rojas; Juan D Gispert
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

6.  Imaging Sex Differences in Regional Brain Metabolism during Acute Opioid Withdrawal.

Authors:  Giovanni C Santoro; Joseph Carrion; Stephen L Dewey
Journal:  J Alcohol Drug Depend       Date:  2017-04-06

7.  Synthesis of fluorine-18 radio-labeled serum albumins for PET blood pool imaging.

Authors:  Falguni Basuli; Changhui Li; Biying Xu; Mark Williams; Karen Wong; Vincent L Coble; Olga Vasalatiy; Jurgen Seidel; Michael V Green; Gary L Griffiths; Peter L Choyke; Elaine M Jagoda
Journal:  Nucl Med Biol       Date:  2014-12-06       Impact factor: 2.408

8.  [11 C]Fluoroform, a Breakthrough for Versatile Labeling of PET Radiotracer Trifluoromethyl Groups in High Molar Activity.

Authors:  Mohammad B Haskali; Victor W Pike
Journal:  Chemistry       Date:  2017-05-17       Impact factor: 5.236

9.  [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot.

Authors:  Mohammed N Tantawy; Carrie K Jones; Ronald M Baldwin; M Sib Ansari; P Jeffrey Conn; Robert M Kessler; Todd E Peterson
Journal:  Nucl Med Biol       Date:  2009-10-03       Impact factor: 2.408

10.  11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls.

Authors:  Robin Goland; Matthew Freeby; Ramin Parsey; Yoshifumi Saisho; Dileep Kumar; Norman Simpson; Joy Hirsch; Martin Prince; Antonella Maffei; J John Mann; Peter C Butler; Ronald Van Heertum; Rudolph L Leibel; Masanori Ichise; Paul E Harris
Journal:  J Nucl Med       Date:  2009-02-17       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.